CurrentCignaPolicy IP0094

Tobramycin Inhalation Solution

Cigna drug coverage policy for tobramycin inhalation solution (Bethkis, Kitabis, TOBI, generics) defining prior authorization requirements, medical necessity criteria for cystic fibrosis and non-CF bronchiectasis, continuation criteria, product-specific preferred-product/step requirements by plan type, and exclusions.

Policy Summary

PayerCigna

PolicyTobramycin Inhalation Solution

Policy CodePolicy IP0094

Change TypeAnnual revisions (7/1/2024; 6/15/2025)

Effective DateJun 15, 2025

Next Review Date

Key ActionPrior Authorization is required; ensure specialist involvement and trial of preferred/generic products per plan rules and request appropriate approval durations (1 year for CF/bronchiectasis; 1 month for continuation).

POLICY UPDATE CHANGES

Added medical necessity criteria, including preferred products, for Individual and Family Plans.

Added TOBI Podhaler as another preferred alternative option for Employer Plans for Cystic Fibrosis.

Updated authorization duration for Continuation of Tobramycin Inhalation Solution Therapy (for conditions other than Cystic Fibrosis or Bronchiectasis) to 1 month (was previously 12 months).

Annual Revision dated 6/15/2025: No criteria changes.

2Covered Indications (CF; Non-CF bronchiectasis)

1Continuation indication (other conditions)

1Explicit exclusion (nasal rinse)

Coverage Summary

covered_with_criteria — Cigna drug coverage policy for tobramycin inhalation solution (Bethkis, Kitabis, TOBI, generics, and specified alternatives) requiring prior authorization. Policy scope includes medical necessity criteria and plan-specific preferred-product/step requirements for cystic fibrosis with Pseudomonas aeruginosa and non-cystic fibrosis bronchiectasis with Pseudomonas aeruginosa, continuation criteria for ongoing courses of therapy, explicit exclusions (e.g., nasal rinse), and product-specific preferred/generic trial requirements that vary by Employer versus Individual and Family plan types.

Plan-Specific Preferred Products & Provider Actions

Prior Authorization

Prior authorization required

Prior Authorization is required for prescription benefit coverage of tobramycin inhalation solution; approvals are provided for specified durations.

1 year for Cystic Fibrosis and Bronchiectasis
1 month (30 days) for continuation of therapy for other conditions

Documentation Required

Specialist involvement required

Medication must be prescribed by or in consultation with a pulmonologist or a physician who specializes in the condition (CF specialist for CF indication).

Pulmonologist or CF specialist required / consult

Step Therapy

Trial of preferred/generic product required (plan-specific)

Plan-specific criteria require a trial of generics or specified preferred alternatives before approving a non-preferred product; examples and affected plan types are listed below.

Generics for Bethkis/Kitabis/TOBI solution (examples: tobramycin inhalation solution generics 300mg/4ml or 300mg/5ml)
TOBI Podhaler as an alternative (Employer Plans)
Plan types affected: Employer; Individual & Family

Billing Rule

Approval duration rules

Approvals are issued for specific durations depending on indication: 1 year for cystic fibrosis and for non-CF bronchiectasis; continuation approvals for other conditions are limited to 1 month (defined as 30 days).

Cystic Fibrosis – approve for 1 year
Bronchiectasis, Non-Cystic Fibrosis – approve for 1 year
Continuation of therapy (other conditions) – approve for 1 month (30 days)

Denial Risk

Exclusion for nasal rinse and other unsupported uses

Tobramycin inhalation solution is not approvable for uses that do not meet medical necessity criteria; specifically, compounding for nasal rinse is excluded and such claims will be considered not medically necessary and denied.

Nasal rinse compounding explicitly not approvable
Any other use not meeting the medical necessity criteria will be considered not medically necessary and denied

Clinical Evidence & Background

Tobramycin inhalation solutions are aminoglycoside antibiotics indicated primarily for management of cystic fibrosis (CF) in patients with Pseudomonas aeruginosa. Guideline evidence (Cystic Fibrosis Foundation) strongly recommends chronic inhaled tobramycin for CF patients ≥ 6 years with persistent P. aeruginosa to improve lung function and reduce exacerbations; eradication regimens favor tobramycin 300 mg twice daily for 28 days for initial/new P. aeruginosa growth. A limited body of supportive evidence exists for use in non-CF bronchiectasis with P. aeruginosa showing reductions in sputum bacterial density and some clinical benefit. Product labeling and policy note safety/efficacy limitations: TOBI and Kitabis indicated for CF patients ≥ 6 years with safety not demonstrated in patients < 6 years or with FEV1 < 25% or > 75% predicted; Bethkis labeling indicates safety not demonstrated in patients < 6 years or with FEV1 < 40% or > 80% predicted.

CFFCFF: chronic inhaled tobramycin strongly recommended for CF patients ≥6 years with persistent P. aeruginosa; recommended for mild disease to reduce exacerbations

EradicationEradication regimen favored: tobramycin 300 mg BID × 28 days for initial/new P. aeruginosa growth

BronchiectasisSupportive evidence: TIS 300 mg improves sputum bacterial density and clinical outcomes in non-CF bronchiectasis with P. aeruginosa

Operational age thresholds (highlighted)

Age for TOBI/Kitabis indication≥ 6 years

Bethkis safety populationSafety and efficacy not demonstrated in patients < 6 years of age

Bronchiectasis age criterion≥ 18 years

Revision History

2024-07-01addition

Added medical necessity criteria, including preferred products, for Individual and Family Plans.

2024-07-01addition

Added TOBI Podhaler as a preferred alternative option for Employer Plans for Cystic Fibrosis.

2024-07-01revision

Updated authorization duration for Continuation of Tobramycin Inhalation Solution Therapy (for conditions other than Cystic Fibrosis or Bronchiectasis) to 1 month (previously 12 months).

2025-06-15administrative_revisionLatest

Administrative annual revision: No criteria changes.